Epidemiological trends of Alpha1-antitrypsin deficiency (AATD) in the UK: prevalence and incidence from 1990 to 2015

Study identification

• EU PAS number:
  EUPAS21791
• Study ID:
  28295
• Official title and acronym:
  Epidemiological trends of Alpha1-antitrypsin deficiency (AATD) in the UK: prevalence and incidence from 1990 to 2015
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  This exploratory protocol aims to determine the epidemiological trends of Alpha1-antitrypsin deficiency (AATD) in the UK: frequency of testing, prevalence and incidence from 1990 to 2015. It will also aim to determine the demographic and clinical characteristics associated with AATD.
• Study status:
  Finalised

Research institutions and networks

Networks

Respiratory Effectiveness Group (REG)

Belgium

Denmark

France

Germany

Greece

Hungary

Italy

Netherlands

Spain

Sweden

United Kingdom

Study timelines

Date when funding contract was signed

Actual: 27/09/2017

Study start date

Actual: 27/09/2017

Data analysis start date

Actual: 04/10/2017

Date of interim report, if expected

Actual: 17/10/2017

Date of final study report

Actual: 01/06/2018

Sources of funding

Other

More details on funding

Respiratory Effectiveness Group

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable